Shanghai Fudan Forward S&T Co., Ltd

Equities

600624

CNE0000006S1

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.05 CNY +2.27% Intraday chart for Shanghai Fudan Forward S&T Co., Ltd +6.58% -29.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Fudan Forward S&T to Auction Office Property For At Least 31 Million Yuan MT
Fudan Forward S&T Chairman Retires MT
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback announced on June 30, 2021, has expired with 5,365,068 shares, representing 0.78% for CNY 35.01 million. CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shanghai Fudan Forward S&T Co., Ltd commences an Equity Buyback Plan for CNY 70 million worth of its shares, under the authorization approved on April 8, 2021. CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Shanghai Fengxian Investment Co., Ltd. completed the acquisition of 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd CI
Shanghai Fengxian Investment Co., Ltd., completed the acquisition of 18.74% stake in Shanghai Fudan Forward S&T Co., Ltd from Fudan University, Endowment Arm. CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Shanghai Fudan Forward S&T Co., Ltd Announces Tax Included Final Cash Dividend for the Full Year of 2019, Payable on August 03, 2020 CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Shanghai Fengxian Investment Co., Ltd. agreed to acquire 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Fudan University, Endowment Arm for nil consideration. CI
Chart Shanghai Fudan Forward S&T Co., Ltd
More charts
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
Calendar
More about the company